Where access and availability are part of the pitch.
Vaccine manufacturers and distributors need digital presence that does more than describe a product: it has to help people actually find where a vaccine is available, alongside the clinical and public health content the category demands.
Vaccines occupy a distinctive space between clinical product and public health intervention, which means content needs both the precision of a regulated claim and the accessibility of public health communication, aimed at both HCPs and the general public.
Content that serves HCP and public audiences appropriately, availability and access information built as a functional tool rather than static text, and claims held to the specific evidence base for the product.
We build the digital tools and content that help people access and understand your vaccines, working within whatever your regulatory and medical teams have approved rather than distribution or policy decisions that sit outside our role.
The scope our work with vaccine companies has operated within.
The build priorities for a public-health-adjacent product differ from a standard prescription treatment. Here is what vaccine companies most often need.
How this work is approached specifically for Vaccines.
What comes up when building for a vaccine manufacturer or distributor.
Yes — eligibility for a given vaccine commonly varies by age, risk group, or region, so we build that logic into the finder rather than presenting one static schedule for every visitor. Your medical and regulatory team supplies the eligibility rules and any updates, and we structure the content so a change to one group’s guidance does not require rebuilding the whole tool.
As current as your underlying data source allows — see vaccine finder tool for how we build to whatever update frequency your supply and distribution system can realistically support, and display that freshness openly to the visitor rather than implying a real-time accuracy the underlying data does not have.
Rarely as one version — patients and healthcare professionals need different depth, different register, and often different regulatory sign-off, so we usually recommend building two versions from the same approved source rather than one blended page. Keeping them structurally separate also makes it easier to update one audience’s content without triggering a full review of the other’s.
We build a dedicated notice pathway for exactly this, since a vaccine site sometimes needs to publish an urgent update faster than the normal content review cycle allows. Your medical and regulatory team still originates and approves the wording, but the publishing path is shortened and flagged separately, so a time-sensitive notice does not queue behind routine content changes.
Related sectors worth reviewing alongside vaccines.
Access and content that need to reach both the public and healthcare professionals. Tell us your situation and we will tell you how we would approach it for a vaccine company.